2
Investors
About
Proxi Biotech develops novel toxoid-based active immunotherapies to treat bacterial re-infections caused by drug-resistant pathogens, focusing on conditions such as recurrent Clostridium difficile and urinary tract infections.
Explore Proxi Biotech's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.